Liraglutide Market Report 2026

The liraglutide market size has grown strongly in recent years. It will grow from $6.88 billion in 2025 to $7.45 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to rising global prevalence of type 2 diabetes, clinical success of glp-1 receptor agonists, need for therapies addressing both glucose control and weight, approval of liraglutide for diabetes and obesity indications, increasing physician confidence in injectable incretin therapies.

The liraglutide market size is expected to see strong growth in the next few years. It will grow to $10.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to growing global obesity burden, increasing preference for weight-centric diabetes treatments, expansion of metabolic disorder screening programs, rising patient demand for effective appetite-suppressing therapies, continued innovation and awareness in glp-1 based treatments. Major trends in the forecast period include strong adoption of liraglutide in type 2 diabetes management, rising use of liraglutide for medical weight management, growing acceptance of injectable glp-1 therapies, expansion of long-term metabolic disease management programs, increasing focus on dual benefits of glycemic control and weight loss.

The growing diabetic population is expected to drive the expansion of the liraglutide market in the coming years. Diabetes is a long-term condition in which the body is unable to effectively regulate blood glucose levels due to inadequate insulin production or reduced insulin effectiveness. The prevalence of diabetes is increasing globally as a result of sedentary lifestyles, poor dietary habits, and rising obesity rates. Diabetes medications such as liraglutide support disease management by mimicking the action of the GLP-1 hormone, which stimulates insulin release, reduces blood glucose levels, and supports weight loss, thereby helping manage type 2 diabetes. For example, in March 2024, according to a report published by the Government of the United Kingdom, a UK-based information source, the proportion of people with type 1 diabetes in England who received all eight recommended care processes at general practitioner practices participating in the National Diabetes Audit rose to 43.8 percent in March 2023, up from 35.2 percent in the previous year. Therefore, the expanding diabetic population is contributing to the growth of the liraglutide market.

Major companies operating in the liraglutide market are focusing on the development of new products, such as generic GLP-1 therapies, to broaden treatment options and meet demand for more affordable alternatives. Generic GLP-1 products are versions of GLP-1 receptor agonists introduced after patent expiry of branded drugs, providing cost effective options for treating type 2 diabetes and obesity. For instance, in June 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, launched the first generic GLP-1 product comparable to Victoza in the United States, addressing the increasing demand for these therapies. Liraglutide injections are prescribed to improve blood sugar control in adults and children aged ten years and older with type 2 diabetes and to reduce the risk of cardiovascular events in adults with type 2 diabetes and existing cardiovascular disease.

In October 2023, Biocon Limited, an India-based biopharmaceutical company, entered into a partnership with Juno Pharmaceuticals to commercialize its vertically integrated and complex formulation of liraglutide. Under the agreement, Biocon is responsible for securing regulatory approval and subsequently manufacturing and supplying liraglutide for the Canadian market. Juno Pharmaceuticals is a Canada-based pharmaceutical company focused on bringing complex and high value generic and biosimilar products to market.

Major companies operating in the liraglutide market are Novo Nordisk A/S.

North America was the largest region in the liraglutide market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liraglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the liraglutide market by increasing the cost of imported active pharmaceutical ingredients, peptide synthesis inputs, and specialized injection device components. These effects have been most prominent in branded products across North America and Europe due to complex global supply chains. Asia-Pacific markets have experienced pricing pressure and supply adjustments linked to trade dependencies. However, tariffs have encouraged localized manufacturing and investment in domestic peptide production, supporting long-term supply resilience.

The liraglutide market research report is one of a series of new reports that provides liraglutide market statistics, including liraglutide industry global market size, regional shares, competitors with a liraglutide market share, detailed liraglutide market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide industry. This liraglutide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liraglutide is a glucagon-like peptide-1 receptor agonist used in the treatment of type 2 diabetes and obesity. It helps control blood glucose levels and supports weight loss by mimicking the natural incretin hormone GLP-1. The drug is administered through subcutaneous injection and works by increasing insulin secretion while reducing appetite. Liraglutide is commercially available under the brand names Victoza for diabetes management and Saxenda for obesity treatment.

The main brands of liraglutide include Victoza and Saxenda. Victoza is a brand formulation of liraglutide used for the management of type 2 diabetes. It is distributed through hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. The medication is used for diabetes treatment and weight management and is utilized across various end users such as hospitals, clinics, and home care settings.

The liraglutide market consists of sales of insulin products, weight management supplements, nutritional supplements, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.